pharma · Geographic Atrophy · Geographic Atrophy Secondary to Age-related Macular Degeneration · APLS
Genzyme Europe
Apellis Europe B.V.
Genzyme Europe is a pharma organization headquartered in WALTHAM, MA, NL. It trades on NYSE under ticker APLS. Primary therapeutic focus areas include Geographic Atrophy, Geographic Atrophy Secondary to Age-related Macul
Gooimeer 10, Naarden, None 1411 DD, NL, WALTHAM, MA HQ
1981 Founded
273 Employees
Public company Type
APLS · NYSE Ticker
Company details
- Status
- Public
- HQ
- Gooimeer 10, Naarden, None 1411 DD, NL, WALTHAM, MA
- Founded
- 1981
- Employees
- 273
- Programs
- 20
- Drugs
- 5
- Patents
- 24
Pegcetacoplan
Phase 3 · small molecule · Paroxysmal Nocturnal Hemoglobinuria
Pegcetacoplan for Paroxysmal Nocturnal Hemoglobinuria is a Phase 3 program (small_molecule) at Apellis Europe B.V. with 2 ClinicalTrials.gov record(s).
Internal code APL2-CP-PNH-204
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Apellis Europe B.V.
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Paroxysmal Nocturnal Hemoglobinuria
- Status
- completed
- Trials
- 2